RxDoctor Payments Data

Jessica Schaller

Acute Care · Clinton Township, MINPI 1144621459

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,164 and has fallen 72.3% since, to $322 in 2025. Among acute care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,923in general payments, 2019–2025

Across 153 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$472
  • Actelion Pharmaceuticals US, Inc.$457
  • Kestra Medical Technology Services, Inc.$409
  • Amgen$357
  • Merck$341
  • Abiomed$267
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$3,65893%
  • Education$2657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,923 in reported general payments places this provider in the 90th percentile of 567 acute care providers in Michigan.

See all acute care providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$190,191
EntrestoSacubitril/Valsartan63$56,290
JardianceEmpagliflozin31$28,466
FarxigaDapagliflozin Propanediol24$21,355
Repatha SureclickEvolocumab14$8,520
Metoprolol Succinate209$3,313
Ranolazine ErRanolazine19$1,905
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$903
Nifedipine ErNifedipine36$797
ClopidogrelClopidogrel Bisulfate22$634
Rosuvastatin Calcium44$562
Atorvastatin Calcium30$538
SotalolSotalol Hcl25$500
Carvedilol44$472
Flecainide Acetate11$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$230$190,191176 claims
NovartisEntresto$472$56,29063 claims
Boehringer IngelheimJardiance$93$28,46631 claims
AstraZenecaFarxiga$178$21,35524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 acute care providers in Michigan.

Other acute care in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →